## IN THE CLAIMS:

Please AMEND the claims to read as set forth in the following listing of the claims:

## **CLAIMS**

- (original) A cell support comprising an RGD-enriched gelatine in which the
  percentage of RGD motifs related to the total number of amino acids is at least 0.4
  and if the RGD-enriched gelatine comprises 350 amino acids or more, each stretch
  of 350 amino acids contains at least one RGD motif.
- 2. (original) A cell support according to claim 1 in which in the RGD-enriched gelatine the percentage is at least 0.6, preferably at least 0.8, more preferably at least 1.0, more preferably at least 1.2 and most preferably at least 1.5.
- (currently amended) A cell support according to claim 1 or 2 in which in the
   RGD-enriched gelatine the number of RGD motifs is at least 4 per 250 amino acids.
- 4. (currently amended) A cell support according to <u>claim 1</u> any of the preceding elaims in which the RGD-enriched gelatine comprises at least 4 RGD motifs, preferably 6, more preferably 8, even more preferably 12 up to and including 16 RGD motifs.
- 5. (currently amended) A cell support according to <u>claim 1</u> any of the preceding <u>claims</u> in which the RGD-enriched gelatine has a molecular weight of about 30 kDa to about 200 kDa.
- 6. (currently amended) A cell support according to <u>claim 1</u> any of the preceding <u>claims</u> in which the RGD-enriched gelatine has a molecular weight of more than 60 kDa, preferably more than 70 kDa.

- 7. (currently amended) A cell support according to <u>claim 1</u> any of the <u>preceding</u> elaims in which the RGD-enriched gelatine has a molecular weight of less than about 150 kDa.
- 8. (currently amended) A cell support according to <u>claim 1 any of the preceding</u> claims in which the RGD-enriched gelatine comprises less than 5% hydroxyproline residues, preferably less than 3%.
- 9. (currently amended) A cell support according to <u>claim 1</u> any-of the preceding claims in which the RGD-enriched gelatine has a net positive charge at pH 7-7.5.
- 10. (currently amended) A cell support according to <u>claim 1</u> any of the <u>preceding</u> elaims in which the RGD-enriched gelatine consists for at least 80% of one or more parts of native human collagen sequences and said parts of native human collagen sequences have a length of at least 30 amino acids.
- 11. (original) A cell support according to claim 10 in which the RGD-enriched gelatine consists of one or more parts of one or more native human collagen sequences.
- 12. (original) An RGD-enriched gelatine in which the percentage of RGD motifs related to the total number of amino acids is at least 0.4 and if the RGD-enriched gelatine comprises 350 amino acids or more, each stretch of 350 amino acids contains at least one RGD motif, said gelatine consists for at least 80% of one or more parts of native human collagen sequences and said parts of native human collagen sequences having a length of at least 30 amino acids.

- 13. (original) An RGD-enriched gelatine according claim 12 wherein the RGD-enriched gelatine has a molecular weight of at most 10 kDa, preferably at most 5 kDa.
- 14. (currently amended) A cell support according to any-of claims 1-11 or comprising an RGD-enriched gelatine according to claim 12, said cell support being a microcarrier.
- 15. (currently amended) A cell support according to any of claims 1–11 or comprising an RGD-enriched gelatine according to claim 12 or 13, said cell support being selected from the group consisting of an RGD-enriched coated implant or transplant material, an RGD-enriched coated scaffold for tissue engineering, (part of) a dental product, (part of) a wound healing product, (part of) artificial skin matrix material and (part of) a tissue adhesive.
- 16. (original) Use of an RGD-enriched gelatine according to claim 12 as a component of drug delivery systems.
- 17. (original) Use of an RGD-enriched gelatine according to claim 13 for inhibition of cancer metastasis.
- 18. (currently amended) Use of an RGD-enriched gelatine according to claim 12 or 13 for prevention of platelet aggregation.
- 19. (original) Use of an RGD-enriched gelatine according to claim 13 after surgery to prevent tissue adhesion.